Inhibitor Therapeutics (INTI) Debt Ratio (2013 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Debt Ratio came in at 0.04 in Q1 2026, up 117.48% YoY from 0.02 in Q1 2025, and up 65.96% on a QoQ basis from 0.02 in Q4 2025.
Inhibitor Therapeutics (INTI) Debt Ratio (2013 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 6 years of Debt Ratio data on file, last reported at 0.04 in Q1 2026.
- Quarterly Debt Ratio rose 117.48% year-over-year to 0.04 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.04 (up 117.48% YoY) and the FY2025 annual result came in at 0.02, changed N/A from the prior year.
- Debt Ratio rose to 0.04 in Q1 2026, from 0.02 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.04 in Q1 2026 to a low of 0.02 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 0.05 |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 0.12 |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 0.03 |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 0.26 |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 0.47 |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 0.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.04 |
| Dec 31, 2025 | 0.02 |
| Sep 30, 2025 | 0.02 |
| Jun 30, 2025 | 0.02 |
| Mar 31, 2025 | 0.02 |
| Mar 31, 2021 | 0.75 |
| Dec 31, 2020 | 0.42 |
| Sep 30, 2020 | 0.18 |
| Jun 30, 2020 | 0.12 |
| Dec 31, 2014 | 0.59 |
| Sep 30, 2014 | 1.51 |
| Jun 30, 2014 | 2.13 |
| Mar 31, 2014 | 45.42 |
| Dec 31, 2013 | 35.84 |
| Sep 30, 2013 | 1,755.25 |